AU2020297166A1 - Method for treating malignant tumor - Google Patents

Method for treating malignant tumor Download PDF

Info

Publication number
AU2020297166A1
AU2020297166A1 AU2020297166A AU2020297166A AU2020297166A1 AU 2020297166 A1 AU2020297166 A1 AU 2020297166A1 AU 2020297166 A AU2020297166 A AU 2020297166A AU 2020297166 A AU2020297166 A AU 2020297166A AU 2020297166 A1 AU2020297166 A1 AU 2020297166A1
Authority
AU
Australia
Prior art keywords
day
phenyl
salt
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020297166A
Other languages
English (en)
Inventor
Kazuo KOBA
Toshiyasu Shimomura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of AU2020297166A1 publication Critical patent/AU2020297166A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020297166A 2019-06-21 2020-06-19 Method for treating malignant tumor Abandoned AU2020297166A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-115496 2019-06-21
JP2019115496 2019-06-21
PCT/JP2020/024113 WO2020256096A1 (ja) 2019-06-21 2020-06-19 悪性腫瘍の治療方法

Publications (1)

Publication Number Publication Date
AU2020297166A1 true AU2020297166A1 (en) 2022-02-17

Family

ID=74040503

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020297166A Abandoned AU2020297166A1 (en) 2019-06-21 2020-06-19 Method for treating malignant tumor

Country Status (8)

Country Link
US (1) US20220354858A1 (https=)
EP (1) EP3988175A4 (https=)
JP (1) JP7574184B2 (https=)
KR (1) KR20220024821A (https=)
AU (1) AU2020297166A1 (https=)
MA (1) MA56549A (https=)
TW (1) TWI856115B (https=)
WO (1) WO2020256096A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
SG11202008435SA (en) 2018-03-19 2020-10-29 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate
EP4284378A4 (en) * 2021-02-01 2024-12-25 Taiho Pharmaceutical Co., Ltd. Ptentreating cancer in patient with pten inactivating mutation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101658274B1 (ko) 2011-04-06 2016-09-22 다이호야쿠힌고교 가부시키가이샤 신규 이미다조 옥사진 화합물 또는 그의 염
DK2657233T3 (da) 2012-01-19 2014-09-22 Taiho Pharmaceutical Co Ltd 3,5-disubstitueret alkynylbenzenforbindelse og salt deraf
NO2868660T3 (https=) * 2012-07-02 2018-05-26
JP6289459B2 (ja) 2013-06-20 2018-03-07 大鵬薬品工業株式会社 ＰＨＬＤＡ１又はＰＩＫ３Ｃ２Ｂの発現に基づくＰＩ３Ｋ／ＡＫＴ／ｍＴＯＲ阻害剤の治療効果の予測方法
CN111943962A (zh) * 2015-02-27 2020-11-17 大鹏药品工业株式会社 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法
EP3424505A4 (en) * 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP4093406A4 (en) * 2020-01-24 2024-02-28 Taiho Pharmaceutical Co., Ltd. IMPROVEMENT OF THE ANTI-TUMORAL ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NEW ANTI-CANCER DRUGS AGAINST CANCER
EP4284378A4 (en) * 2021-02-01 2024-12-25 Taiho Pharmaceutical Co., Ltd. Ptentreating cancer in patient with pten inactivating mutation

Also Published As

Publication number Publication date
TW202114691A (zh) 2021-04-16
US20220354858A1 (en) 2022-11-10
JPWO2020256096A1 (https=) 2020-12-24
WO2020256096A1 (ja) 2020-12-24
MA56549A (fr) 2022-04-27
TWI856115B (zh) 2024-09-21
EP3988175A4 (en) 2023-06-28
KR20220024821A (ko) 2022-03-03
JP7574184B2 (ja) 2024-10-28
EP3988175A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
USRE45105E1 (en) Method of treating cancer by co-administration of anticancer agents
US11975002B2 (en) Preparation and composition for treatment of malignant tumors
Ravnan et al. Vemurafenib in patients with BRAF V600E mutation–positive advanced melanoma
US11446309B2 (en) Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
JP7574184B2 (ja) 悪性腫瘍の治療方法
TWI746449B (zh) 使用阿吡莫德治療癌症之方法
TWI530287B (zh) 組合療法
TWI747868B (zh) 含有免疫調節劑之抗腫瘤劑及抗腫瘤效果增強劑
JP6911048B2 (ja) がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法
AU2020228514B2 (en) Cancer therapy using 3,5-disubstituted benzene alkynyl compound and immune checkpoint inhibitor
CN113194952A (zh) Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
JP7805285B2 (ja) ３，５－二置換ベンゼンアルキニル化合物とｍｅｋ阻害剤とを用いた癌治療法
EP2999465A1 (en) Specific cancer treatment regimens with ganetespib
WO2020005932A1 (en) Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites
RU2816126C2 (ru) Способ лечения злокачественной опухоли
WO2025245045A1 (en) Methods of treating lung cancer
HK40108632A (zh) 癌的治疗或预防用药物
Aicher et al. 203 Perifosine in combination with antimetabolites induces synergistic effects on cytotoxicity and apoptosis in human colon, multiple myeloma, breast, renal, and liver tumor cell lines
JP2015163591A (ja) 抗癌剤の併用による癌治療方法

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted